BioSpace News Archive

AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2022, and provided recent corporate updates.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Dante Labs , a global leader in genomics and precision medicine, is pleased to announce the Italian Ministry of Economic Development has selected Dante to develop and pilot the first fully-CE-IVD, clinically approved whole genome sequencing (WGS) test for the citizens of Italy to be named the Dante Citizen Test.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the formation of its scientific advisory board (SAB).

Elo Life Systems , a company that is empowering the future of sustainable and healthy food, announced that Todd Rands has been appointed as its new Chief Executive Officer.

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex” or the ‘Company’), a clinical stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that IHL-216A was observed to have a strong neuroprotective effect in a widely known model of sports concussion.

Conformis, Inc. announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright Global Investment Conference.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the first quarter ended March 31, 2022.